Skip to content

Over 50's more likely to have elevated lipids and glucose during HIV therapy

HIV/HCV coinfected individuals have an increased risk of cardiovascular disease

New treatment for facial fat loss approved in US

After 48 weeks of study, and 24 weeks in the real world, darunavir continues to show staying power

TB-related immune reaction to HIV therapy occurs 20 months after TB treatment first started - is this a record?

Atazanavir: genetic predictors for hyperbilirubinemia found

Is HIV causing cardiovascular disease by its own effects on cholesterol?

Genetic link found with tenofovir-associated kidney problems

Many patients taking efavirez experience long-term CNS side-effects